Boston Scientific Stock Gains 3% After Earnings Beat and Upbeat Guidance

Dow Jones01-31

Boston Scientific Corp.’s stock gained 3.2% early Wednesday, after it beat estimates for the fourth quarter and offered upbeat guidance for 2024.

The Marlborough, Mass.-based medical technology company posted net income of $504 million, or 34 cents a share, for the quarter, up from $126 million, or 9 cents a share, in the year-earlier period. Excluding special items, the company had EPS of 55 cents, ahead of the 51 cent FactSet consensus. Sales rose 14.9% to $3.725 billion, well ahead of the $3.593 billion FactSet consensus.

The company is now expecting net sales to rise 8.5% to 9.5% in 2024. It expects EPS of $1.38 to $1.42 and adjusted EPS of $2.23 to $2.27. The FactSet consensus is for sales to rise 8% and for EPS of $2.24.

The stock has gained 33% in the last 12 months, while the S&P 500 has gained 20.8%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment